QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the second quarter of 2025.
Press release date / time: Tuesday, August 5, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time.
Conference call date / time: Wednesday, August 6, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time.
Three options for joining the conference call
Register for call back connection - Click here: Connect me
Service is available 15 minutes before the call starts
Dial-in by phone
U.S.: +1 929 477 0402
UK: +44 (0)330 165 3655
GER: +49 (0)69 6610 2480
Conference ID: 1992038
To avoid waiting time, please join the event conference 5-10 minutes prior to the start time.
Access the audio webcast - Click here: Access Webcast
A conference call replay will be available by using the following link:
https://event.webcasts.com/viewer/event.jsp?ei=1709551&tp_key=978ad5a0e6
Contact: IR@qiagen.com
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and costeffective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of March 31, 2025, QIAGEN employed more than 5,600 people in over 35 locations worldwide. For more information, visit www.qiagen.com.
category: Financial
View source version on businesswire.com: https://www.businesswire.com/news/home/20250708505880/en/
Contacts
John Gilardi
Vice President Head of Corporate Communications
+49 2103 29 11711
+49 152 018 11711
+1 240 686 2222
Email: ir@qiagen.com
Domenica Martorana
Associate Director Investor Relations
+49 2103 29 11244
+49 152 018 11244
Email: ir@qiagen.com